Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Summary

This phase II trial is studying how well bevacizumab works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.

Timeline

Start

2006-03

Primary completion

2011-07

Completion

2011-07

Drugs

Indications